AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions of claims in the application:

1. (Currently Amended) ~~Use of~~ A method for treating deafness in a subject, comprising administering to said subject a pharmaceutical composition that comprises (a) at least one kinase inhibitor ~~for making drugs for~~ or a pharmaceutically acceptable salt thereof and (b) a pharmaceutically acceptable carrier, in an amount effective for inducing differentiation of supernumerary hair cells and Deiters' cells in ~~the developing~~ an organ of Corti ~~for treating deafness~~ of said subject.

2. (Currently Amended) The ~~use~~ method of claim 1, wherein said kinase inhibitor is ~~selected in the group comprising purine derivatives~~ a purine derivative.

3. (Currently Amended) The ~~use~~ method of claim 2, wherein said purine ~~derivatives are~~ derivative is selected ~~in~~ from the group ~~comprising~~ consisting of roscovitine, ~~indirubins and purvulanols~~ indirubin and purvalanol.

4. (Currently Amended) The ~~use~~ method of claim 1, wherein said kinase ~~inhibitors are~~ inhibitor is administered parenterally, rectally, topically, transdermally or orally.

5. (Currently Amended) The ~~use~~ method of claim 4, wherein said kinase ~~inhibitors are~~ inhibitor is administered by ~~the~~ oral or by injectable route.

6. (Currently Amended) The ~~use~~ method of claim 5, wherein said kinase ~~inhibitors are under~~ inhibitor is in the form of a lozenge ~~lozenges~~, a compressed tablet ~~compressed tablets~~, a pill ~~pills~~, a tablet ~~tablets~~, a capsule ~~capsules~~, drops, a syrup ~~syrups~~, a suspension ~~suspensions~~ or an emulsion ~~emulsions~~.

7. (Currently Amended) The ~~use~~ method of claim [[4]] 1, wherein ~~the~~ said pharmaceutical ~~compositions comprise~~ composition comprises 100 to 1000 mg of ~~active principle~~ said kinase inhibitor or said salt per dose unit~~, preferably 300 to 600 mg~~.

8. (Currently Amended) The ~~use~~ method of claim 5, wherein said kinase ~~inhibitors are~~ inhibitor is administered ~~under~~ in the form of an injectable ~~solutions~~ solution for ~~the~~ an intravenous, a subcutaneous or an intramuscular route, formulated from a sterile or a sterilizable solution ~~solutions~~, or ~~under~~ in the form of a suspension ~~suspensions~~ or an emulsion ~~emulsions~~.

9. (Currently Amended) The ~~use~~ method of claim 8, wherein said injectable ~~forms comprise~~ solution comprises 100-1000 mg of said ~~compound~~ kinase inhibitor or ~~a pharmaceutically acceptable~~ said salt ~~thereof preferably 300 to 600, per dose unit~~.

10. (Canceled)

11. (New) The method of claim 7, wherein said pharmaceutical composition comprises 300-600 mg of said kinase inhibitor or said salt per dose unit.

12. (New) The method of claim 9, wherein said injectable solution comprises 300-600 mg of said kinase inhibitor or said salt.

13. (New) The method of claim 1, wherein said salt is an acid addition salt.

14. (New) The method of claim 13, wherein said acid is selected from the group consisting of acetic acid, ascorbic acid, maleic acid, phosphoric acid, salicylic acid and tartaric acid.